Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

被引：0
作者：
Buka, Richard J. [1 ]
Sutton, David J. [2 ]
Nicolson, Phillip L. R. [1 ,3 ]
机构：
[1] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, England
[2] Univ Hosp North Midlands NHS Trust, Staffordshire Thrombosis & Anticoagulat Serv, Stoke on trent, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Dept Clin Haematol, Birmingham, England
来源：
JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2024年 / 57卷 / 04期
关键词：
TRIALS;
D O I：
10.1007/s11239-024-02948-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：739 / 741
页数：3
相关论文
共 8 条
  • [1] Cohen AT., 2022, J AM COLL EMERG PHYS, V3, P1
  • [2] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
    Costa, Olivia S.
    Connolly, Stuart J.
    Sharma, Mukul
    Beyer-Westendorf, Jan
    Christoph, Mary J.
    Lovelace, Belinda
    Coleman, Craig I.
    [J]. CRITICAL CARE, 2022, 26 (01)
  • [3] Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes
    Dahabreh, Issa J.
    Sheldrick, Radley C.
    Paulus, Jessica K.
    Chung, Mei
    Varvarigou, Vasileia
    Jafri, Haseeb
    Rassen, Jeremy A.
    Trikalinos, Thomas A.
    Kitsios, Georgios D.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (15) : 1893 - 1901
  • [4] Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey
    Hemkens, Lars G.
    Contopoulos-Ioannidis, Despina G.
    Ioannidis, John P. A.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
  • [5] Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds
    Keinath, Jason J.
    Lekura, Jona
    Hauser, Christian D.
    Bajwa, Manisha K.
    Bloome, Michael E.
    Kalus, James S.
    Jones, Mathew C.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2023, 56 (02) : 315 - 322
  • [6] Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study
    Ren, Jinma
    Cislo, Paul
    Cappelleri, Joseph C. C.
    Hlavacek, Patrick
    DiBonaventura, Marco
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2023, 23 (01)
  • [7] Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
    Sutton, S. Scott
    Magagnoli, Joseph
    Cummings, Tammy H.
    Dettling, Theresa
    Lovelace, Belinda
    Christoph, Mary J.
    Hardin, James W.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2023, 56 (01) : 137 - 146
  • [8] Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses Results of 32 Clinical Trials
    Wang, Shirley V.
    Schneeweiss, Sebastian
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (16): : 1376 - 1385
1